Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

Achieving a pathologic complete response after neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial demonstrated a significant survival improvement with capecitabine in patients with residual invasive disease after neoadjuvant chemotherapy, and the KATHERI...

Descripción completa

Detalles Bibliográficos
Autores principales: Caparica, Rafael, Lambertini, Matteo, Pondé, Noam, Fumagalli, Debora, de Azambuja, Evandro, Piccart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951/
https://www.ncbi.nlm.nih.gov/pubmed/30833989
http://dx.doi.org/10.1177/1758835919827714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951/
https://www.ncbi.nlm.nih.gov/pubmed/30833989
http://dx.doi.org/10.1177/1758835919827714

Ejemplares similares